{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:58:57Z","timestamp":1777640337915,"version":"3.51.4"},"publisher-location":"Cham","reference-count":47,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031803956","type":"print"},{"value":"9783031803963","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-80396-3_1","type":"book-chapter","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T03:59:31Z","timestamp":1742356771000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["What Is New in Diagnostics and Management of Medullary Thyroid Carcinoma"],"prefix":"10.1007","author":[{"given":"Friedhelm","family":"Raue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Frank-Raue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"issue":"3","key":"1_CR1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12020-020-02332-2","volume":"69","author":"V Amodru","year":"2020","unstructured":"Amodru V, Taieb D, Guerin C, Romanet P, Paladino N, Brue T et al (2020) MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives. Endocrine 69(3):496\u2013503. https:\/\/doi.org\/10.1007\/s12020-020-02332-2","journal-title":"Endocrine"},{"issue":"8","key":"1_CR2","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.3390\/cancers15082333","volume":"15","author":"M Broecker-Preuss","year":"2023","unstructured":"Broecker-Preuss M, Simon D, Fries M, Kornely E, Weber M, Vardarli I et al (2023) Update on calcitonin screening for medullary thyroid carcinoma and the results of a retrospective analysis of 12,984 patients with thyroid nodules. Cancers (Basel) 15(8):2333. https:\/\/doi.org\/10.3390\/cancers15082333","journal-title":"Cancers (Basel)"},{"key":"1_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.754565","volume":"12","author":"S Censi","year":"2021","unstructured":"Censi S, Di Stefano M, Repaci A, Benvenuti T, Manso J, Pagotto U et al (2021) Basal and calcium-stimulated Procalcitonin for the diagnosis of medullary thyroid cancers: lights and shadows. Front Endocrinol (Lausanne) 12:754565. https:\/\/doi.org\/10.3389\/fendo.2021.754565","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2023.0482","volume":"34","author":"S Censi","year":"2024","unstructured":"Censi S, Galuppini F, Clausi C, Battheu F, Manso J, Piva I et al (2024) Tumor grade and molecular characteristics associated with survival in sporadic medullary thyroid carcinoma. Thyroid 34(2):177\u2013185. https:\/\/doi.org\/10.1089\/thy.2023.0482","journal-title":"Thyroid"},{"issue":"3","key":"1_CR5","doi-asserted-by":"publisher","first-page":"e9686","DOI":"10.1097\/MD.0000000000009686","volume":"97","author":"JB Choi","year":"2018","unstructured":"Choi JB, Lee SG, Kim MJ, Kim TH, Ban EJ, Lee CR et al (2018) Dynamic risk stratification in medullary thyroid carcinoma: single institution experiences. Medicine (Baltimore) 97(3):e9686. https:\/\/doi.org\/10.1097\/MD.0000000000009686","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"1_CR6","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.surg.2023.09.003","volume":"174","author":"H Dralle","year":"2023","unstructured":"Dralle H, Brandenburg T, Weber F, Fuhrer-Sakel D, Theurer S, Baba HA et al (2023) Sporadic noninvasive medullary thyroid neoplasm: a desmoplasia-negative unifocal nonmetastatic tumor cured by hemithyroidectomy. Surgery 174(6):1356\u20131362. https:\/\/doi.org\/10.1016\/j.surg.2023.09.003","journal-title":"Surgery"},{"issue":"11","key":"1_CR7","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1373\/clinchem.2018.291369","volume":"64","author":"G Eisenhofer","year":"2018","unstructured":"Eisenhofer G, Prejbisz A, Peitzsch M, Pamporaki C, Masjkur J, Rogowski-Lehmann N et al (2018) Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated O-methylated catecholamine metabolites. Clin Chem 64(11):1646\u20131656. https:\/\/doi.org\/10.1373\/clinchem.2018.291369","journal-title":"Clin Chem"},{"issue":"9","key":"1_CR8","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/bjs\/znab106","volume":"108","author":"F Fanget","year":"2021","unstructured":"Fanget F, Demarchi MS, Maillard L, Lintis A, Decaussin M, Lifante JC (2021) Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels. Br J Surg 108(9):1064\u20131071. https:\/\/doi.org\/10.1093\/bjs\/znab106","journal-title":"Br J Surg"},{"issue":"5","key":"1_CR9","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1210\/endrev\/bnad013","volume":"44","author":"ML Gild","year":"2023","unstructured":"Gild ML, Clifton-Bligh RJ, Wirth LJ, Robinson BG (2023) Medullary thyroid cancer: updates and challenges. Endocr Rev 44(5):934\u2013946. https:\/\/doi.org\/10.1210\/endrev\/bnad013","journal-title":"Endocr Rev"},{"issue":"12","key":"1_CR10","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1210\/clinem\/dgab564","volume":"106","author":"L Giovanella","year":"2021","unstructured":"Giovanella L, Garo ML, Ceriani L, Paone G, Campenni A, D\u2019Aurizio F (2021) Procalcitonin as an alternative tumor marker of medullary thyroid carcinoma. J Clin Endocrinol Metab 106(12):3634\u20133643. https:\/\/doi.org\/10.1210\/clinem\/dgab564","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","volume":"47","author":"L Giovanella","year":"2020","unstructured":"Giovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg FA, Luster M (2020) EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 47(1):61\u201377. https:\/\/doi.org\/10.1007\/s00259-019-04458-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"20","key":"1_CR12","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","volume":"389","author":"J Hadoux","year":"2023","unstructured":"Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M et al (2023) Phase 3 trial of Selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med 389(20):1851\u20131861. https:\/\/doi.org\/10.1056\/NEJMoa2309719","journal-title":"N Engl J Med"},{"issue":"1","key":"1_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2213-8587(15)00337-X","volume":"4","author":"J Hadoux","year":"2016","unstructured":"Hadoux J, Pacini F, Tuttle RM, Schlumberger M (2016) Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol 4(1):64\u201371. https:\/\/doi.org\/10.1016\/S2213-8587(15)00337-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"1_CR14","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.3390\/cancers15072125","volume":"15","author":"M Holm","year":"2023","unstructured":"Holm M, Vestergaard P, Poulsen MM, Rasmussen AK, Feldt-Rasmussen U, Bay M et al (2023) Primary hyperparathyroidism in multiple endocrine neoplasia type 2A in Denmark 1930-2021: a nationwide population-based retrospective study. Cancers (Basel) 15(7):2125. https:\/\/doi.org\/10.3390\/cancers15072125","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1_CR15","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.21037\/qims-22-968","volume":"13","author":"L Jiang","year":"2023","unstructured":"Jiang L, Zhu HB, Liang ZW, Chen L, Sun XM, Shao YH, Chen LZ (2023) Comparison of the diagnostic performance and clinical role of different ultrasound-based thyroid malignancy risk stratification systems for medullary thyroid carcinoma. Quant Imaging Med Surg 13(6):3776\u20133788. https:\/\/doi.org\/10.21037\/qims-22-968","journal-title":"Quant Imaging Med Surg"},{"issue":"4","key":"1_CR16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1089\/thy.2020.0167","volume":"31","author":"A Kotwal","year":"2021","unstructured":"Kotwal A, Erickson D, Geske JR, Hay ID, Castro MR (2021) Predicting outcomes in sporadic and hereditary medullary thyroid carcinoma over two decades. Thyroid 31(4):616\u2013626. https:\/\/doi.org\/10.1089\/thy.2020.0167","journal-title":"Thyroid"},{"issue":"3","key":"1_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1373\/clinchem.2010.151688","volume":"57","author":"J Kratzsch","year":"2011","unstructured":"Kratzsch J, Petzold A, Raue F, Reinhardt W, Brocker-Preuss M, Gorges R et al (2011) Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. Clin Chem 57(3):467\u2013474. https:\/\/doi.org\/10.1373\/clinchem.2010.151688","journal-title":"Clin Chem"},{"issue":"11","key":"1_CR18","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1515\/cclm-2021-0428","volume":"59","author":"J Kratzsch","year":"2021","unstructured":"Kratzsch J, Willenberg A, Frank-Raue K, Kempin U, Rocktaschel J, Raue F (2021) Procalcitonin measured by three different assays is an excellent tumor marker for the follow-up of patients with medullary thyroid carcinoma. Clin Chem Lab Med 59(11):1861\u20131868. https:\/\/doi.org\/10.1515\/cclm-2021-0428","journal-title":"Clin Chem Lab Med"},{"key":"1_CR19","doi-asserted-by":"publisher","first-page":"1893047","DOI":"10.1155\/2019\/1893047","volume":"2019","author":"SV Kushchayev","year":"2019","unstructured":"Kushchayev SV, Kushchayeva YS, Tella SH, Glushko T, Pacak K, Teytelboym OM (2019) Medullary thyroid carcinoma: an update on imaging. J Thyroid Res 2019:1893047. https:\/\/doi.org\/10.1155\/2019\/1893047","journal-title":"J Thyroid Res"},{"issue":"1","key":"1_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s12020-015-0849-6","volume":"53","author":"H Kwon","year":"2016","unstructured":"Kwon H, Kim WG, Jeon MJ, Song DE, Lee YM, Sung TY et al (2016) Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy. Endocrine 53(1):174\u2013181. https:\/\/doi.org\/10.1007\/s12020-015-0849-6","journal-title":"Endocrine"},{"issue":"5","key":"1_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/RLU.0000000000002940","volume":"45","author":"SW Lee","year":"2020","unstructured":"Lee SW, Shim SR, Jeong SY, Kim SJ (2020) Comparison of 5 different PET radiopharmaceuticals for the detection of recurrent medullary thyroid carcinoma: a network meta-analysis. Clin Nucl Med 45(5):341\u2013348. https:\/\/doi.org\/10.1097\/RLU.0000000000002940","journal-title":"Clin Nucl Med"},{"issue":"2","key":"1_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1089\/thy.2014.0277","volume":"25","author":"SC Lindsey","year":"2015","unstructured":"Lindsey SC, Ganly I, Palmer F, Tuttle RM (2015) Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. Thyroid 25(2):242\u2013249. https:\/\/doi.org\/10.1089\/thy.2014.0277","journal-title":"Thyroid"},{"issue":"2","key":"1_CR23","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1002\/bjs.10746","volume":"105","author":"A Machens","year":"2018","unstructured":"Machens A, Elwerr M, Lorenz K, Weber F, Dralle H (2018) Long-term outcome of prophylactic thyroidectomy in children carrying RET germline mutations. Br J Surg 105(2):e150\u2013e157. https:\/\/doi.org\/10.1002\/bjs.10746","journal-title":"Br J Surg"},{"issue":"2","key":"1_CR24","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12020-020-02232-5","volume":"68","author":"A Machens","year":"2020","unstructured":"Machens A, Elwerr M, Lorenz K, Weber F, Dralle H (2020) 100-year evolution of precision medicine and surgery for multiple endocrine neoplasia type 2A. Endocrine 68(2):368\u2013376. https:\/\/doi.org\/10.1007\/s12020-020-02232-5","journal-title":"Endocrine"},{"issue":"2","key":"1_CR25","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.surg.2021.07.035","volume":"171","author":"A Machens","year":"2022","unstructured":"Machens A, Kaatzsch P, Lorenz K, Horn LC, Wickenhauser C, Schmid KW et al (2022) Abandoning node dissection for desmoplasia-negative encapsulated unifocal sporadic medullary thyroid cancer. Surgery 171(2):360\u2013367. https:\/\/doi.org\/10.1016\/j.surg.2021.07.035","journal-title":"Surgery"},{"issue":"9","key":"1_CR26","doi-asserted-by":"publisher","first-page":"e734","DOI":"10.1210\/clinem\/dgad156","volume":"108","author":"A Machens","year":"2023","unstructured":"Machens A, Lorenz K, Brandenburg T, Fuhrer-Sakel D, Weber F, Dralle H (2023) The changing face of multiple endocrine neoplasia 2A: from symptom-based to preventative medicine. J Clin Endocrinol Metab 108(9):e734\u2013e742. https:\/\/doi.org\/10.1210\/clinem\/dgad156","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/jamaoto.2023.4376","volume":"150","author":"YV Mao","year":"2024","unstructured":"Mao YV, Hughes EG, Steinmetz D, Troob S, Kim J, Tseng CH et al (2024) Extent of surgery for medullary thyroid cancer and prevalence of occult contralateral foci. JAMA Otolaryngol Head Neck Surg 150(3):209\u2013214. https:\/\/doi.org\/10.1001\/jamaoto.2023.4376","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"1_CR28","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/po.21.00127","volume":"5","author":"A Mweempwa","year":"2021","unstructured":"Mweempwa A, Xu H, Vissers JHA, Tothill RW, Pattison AD, Fellowes AP et al (2021) Novel RET fusion RET-SEPTIN9 predicts response to selective RET inhibition with selpercatinib in malignant pheochromocytoma. JCO Precis Oncol 5:1160\u20131165. https:\/\/doi.org\/10.1200\/po.21.00127","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"1_CR29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/bjs\/znaa047","volume":"108","author":"MB Niederle","year":"2021","unstructured":"Niederle MB, Riss P, Selberherr A, Koperek O, Kaserer K, Niederle B, Scheuba C (2021) Omission of lateral lymph node dissection in medullary thyroid cancer without a desmoplastic stromal reaction. Br J Surg 108(2):174\u2013181. https:\/\/doi.org\/10.1093\/bjs\/znaa047","journal-title":"Br J Surg"},{"issue":"7","key":"1_CR30","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1089\/thy.2019.0785","volume":"30","author":"MB Niederle","year":"2020","unstructured":"Niederle MB, Scheuba C, Riss P, Selberherr A, Koperek O, Niederle B (2020) Early diagnosis of medullary thyroid cancer: are calcitonin stimulation tests still indicated in the era of highly sensitive calcitonin immunoassays? Thyroid 30(7):974\u2013984. https:\/\/doi.org\/10.1089\/thy.2019.0785","journal-title":"Thyroid"},{"issue":"1","key":"1_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000493977","volume":"8","author":"EM Opsahl","year":"2019","unstructured":"Opsahl EM, Akslen LA, Schlichting E, Aas T, Brauckhoff K, Hagen AI et al (2019) Trends in diagnostics, surgical treatment, and prognostic factors for outcomes in medullary thyroid carcinoma in Norway: a Nationwide population-based study. Eur Thyroid J 8(1):31\u201340. https:\/\/doi.org\/10.1159\/000493977","journal-title":"Eur Thyroid J"},{"issue":"1","key":"1_CR32","doi-asserted-by":"publisher","first-page":"15663","DOI":"10.1038\/s41598-023-42907-3","volume":"13","author":"H Park","year":"2023","unstructured":"Park H, Ryu HJ, Heo J, Chung MK, Son YI, Kim JH et al (2023) Preoperative identification of low-risk medullary thyroid carcinoma: potential application to reduce total thyroidectomy. Sci Rep 13(1):15663. https:\/\/doi.org\/10.1038\/s41598-023-42907-3","journal-title":"Sci Rep"},{"issue":"9","key":"1_CR33","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1089\/thy.2022.0189","volume":"32","author":"GW Randolph","year":"2022","unstructured":"Randolph GW, Sosa JA, Hao Y, Angell TE, Shonka DC Jr, LiVolsi VA et al (2022) Preoperative identification of medullary thyroid carcinoma (MTC): clinical validation of the Afirma MTC RNA-sequencing classifier. Thyroid 32(9):1069\u20131076. https:\/\/doi.org\/10.1089\/thy.2022.0189","journal-title":"Thyroid"},{"issue":"9","key":"1_CR34","doi-asserted-by":"publisher","first-page":"e3582","DOI":"10.1210\/clinem\/dgab326","volume":"106","author":"F Raue","year":"2021","unstructured":"Raue F, Bruckner T, Frank-Raue K (2021) Similar stage-dependent survival and outcome in sporadic and hereditary medullary thyroid carcinoma. J Clin Endocrinol Metab 106(9):e3582\u2013e3591. https:\/\/doi.org\/10.1210\/clinem\/dgab326","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1_CR35","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1007\/s00259-017-3759-4","volume":"44","author":"AR Romero-Lluch","year":"2017","unstructured":"Romero-Lluch AR, Cuenca-Cuenca JI, Guerrero-Vazquez R, Martinez-Ortega AJ, Tirado-Hospital JL, Borrego-Dorado I, Navarro-Gonzalez E (2017) Diagnostic utility of PET\/CT with (18)F-DOPA and (18)F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur J Nucl Med Mol Imaging 44(12):2004\u20132013. https:\/\/doi.org\/10.1007\/s00259-017-3759-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1_CR36","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","volume":"17","author":"D Salvatore","year":"2021","unstructured":"Salvatore D, Santoro M, Schlumberger M (2021) The importance of the RET gene in thyroid cancer and therapeutic implications. Nat Rev Endocrinol 17(5):296\u2013306. https:\/\/doi.org\/10.1038\/s41574-021-00470-9","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"1_CR37","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3109\/0284186X.2015.1070963","volume":"55","author":"P Siironen","year":"2016","unstructured":"Siironen P, Hagstrom J, Maenpaa HO, Louhimo J, Arola J, Haglund C (2016) Lymph node metastases and elevated postoperative calcitonin: predictors of poor survival in medullary thyroid carcinoma. Acta Oncol 55(3):357\u2013364. https:\/\/doi.org\/10.3109\/0284186X.2015.1070963","journal-title":"Acta Oncol"},{"issue":"1","key":"1_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1089\/thy.2023.0363","volume":"34","author":"V Subbiah","year":"2024","unstructured":"Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW et al (2024) Pralsetinib in patients with advanced\/metastatic rearranged during transfection (RET)-altered thyroid cancer: updated efficacy and safety data from the ARROW study. Thyroid 34(1):26\u201340. https:\/\/doi.org\/10.1089\/thy.2023.0363","journal-title":"Thyroid"},{"issue":"10","key":"1_CR39","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","volume":"46","author":"D Ta\u00efeb","year":"2019","unstructured":"Ta\u00efeb D, Hicks RJ, Hindi\u00e9 E, Guillet BA, Avram A, Ghedini P et al (2019) European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 46(10):2112\u20132137. https:\/\/doi.org\/10.1007\/s00259-019-04398-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12020-021-02892-x","volume":"75","author":"P Trimboli","year":"2022","unstructured":"Trimboli P, Giannelli J, Marques B, Piccardo A, Crescenzi A, Deandrea M (2022) Head-to-head comparison of FNA cytology vs. calcitonin measurement in FNA washout fluids (FNA-CT) to diagnose medullary thyroid carcinoma. A systematic review and meta-analysis. Endocrine 75(1):33\u201339. https:\/\/doi.org\/10.1007\/s12020-021-02892-x","journal-title":"Endocrine"},{"issue":"1","key":"1_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1530\/EJE-18-1008","volume":"181","author":"O Twito","year":"2019","unstructured":"Twito O, Grozinsky-Glasberg S, Levy S, Bachar G, Gross DJ, Benbassat C et al (2019) Clinico-pathologic and dynamic prognostic factors in sporadic and familial medullary thyroid carcinoma: an Israeli multi-center study. Eur J Endocrinol 181(1):13\u201321. https:\/\/doi.org\/10.1530\/EJE-18-1008","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"1_CR42","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3390\/cancers11070909","volume":"11","author":"AR Vyakaranam","year":"2019","unstructured":"Vyakaranam AR, Crona J, Norlen O, Granberg D, Garske-Roman U, Sandstrom M et al (2019) Favorable outcome in patients with pheochromocytoma and paraganglioma treated with (177)Lu-DOTATATE. Cancers (Basel) 11(7):909. https:\/\/doi.org\/10.3390\/cancers11070909","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1_CR43","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr","year":"2015","unstructured":"Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG, American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6):567\u2013610. https:\/\/doi.org\/10.1089\/thy.2014.0335","journal-title":"Thyroid"},{"issue":"1","key":"1_CR44","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1200\/JCO.21.01329","volume":"40","author":"B Xu","year":"2022","unstructured":"Xu B, Fuchs TL, Ahmadi S, Alghamdi M, Alzumaili B, Bani MA et al (2022) International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma. J Clin Oncol 40(1):96\u2013104. https:\/\/doi.org\/10.1200\/JCO.21.01329","journal-title":"J Clin Oncol"},{"key":"1_CR45","doi-asserted-by":"publisher","first-page":"1015319","DOI":"10.3389\/fendo.2022.1015319","volume":"13","author":"B Yang","year":"2022","unstructured":"Yang B, Niu G, Li X, Ma F, Ma Y, Hu S (2022) Lobectomy may be more appropriate for patients with early-stage medullary thyroid cancer older than 60 years old. Front Endocrinol (Lausanne) 13:1015319. https:\/\/doi.org\/10.3389\/fendo.2022.1015319","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"1_CR46","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1089\/thy.2019.0579","volume":"30","author":"T Yeh","year":"2020","unstructured":"Yeh T, Yeung M, Sherman EJ, Tuttle RM, Sabra MM (2020) Structural doubling time predicts overall survival in patients with medullary thyroid cancer in patients with rapidly progressive metastatic medullary thyroid cancer treated with molecular targeted therapies. Thyroid 30(8):1112\u20131119. https:\/\/doi.org\/10.1089\/thy.2019.0579","journal-title":"Thyroid"},{"issue":"10","key":"1_CR47","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/jamasurg.2022.3544","volume":"157","author":"L Yip","year":"2022","unstructured":"Yip L, Duh QY, Wachtel H, Jimenez C, Sturgeon C, Lee C et al (2022) American Association of Endocrine Surgeons Guidelines for adrenalectomy: executive summary. JAMA Surg 157(10):870\u2013877. https:\/\/doi.org\/10.1001\/jamasurg.2022.3544","journal-title":"JAMA Surg"}],"container-title":["Recent Results in Cancer Research","Medullary Thyroid Carcinoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-80396-3_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T03:59:35Z","timestamp":1742356775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-80396-3_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031803956","9783031803963"],"references-count":47,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-80396-3_1","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"20 March 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}